Clinical trials followed in January 2016 and concluded in May 2017
All compounds are intended strictly for laboratory research use and are not approved for human consumption.
State Legislative Landscape in 2025 Despite a significant number of bills in 2023 and 2024 that would have required mandated coverage of GLP-1s in Medicaid, state employee health plans, or for health insurers regulated by the state, only Arkansas, California, Maryland, New Mexico, Pennsylvania, and Texas have introduced legislation mandating coverage in 2025 to date
Transitioning from tirzepatide Researchers switching from tirzepatide to retatrutide sometimes experience increased side effects because of the added glucagon receptor component
More About Us Book a consultation today and take the first step toward a healthier, happier you with our medically supervised weight loss program.
The following sections explore these aspects in more detail